7 completed, 3 unknown, 2 recruiting, 1 active not recruiting. 2 Phase 1, 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 1, Terminated 1 |
| Phase 3 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow SARS-CoV-2 Vaccine: new trials by email Literature Review of SARS-CoV-2 Vaccine trials Research Report on SARS-CoV-2 Vaccine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age mRNA-1083, Placebo, Licensed Influenza Vaccine - COVID-19, Influenza | Phase 3 | Completed | ModernaTX, Inc. | 2457 | 2024-11-18 | 2025-12-02 |
| Impact Of Kidney Failure On The Regulation Of Humoral Response To Vaccination Influenza vaccination, SARS-CoV-2 vaccine - Chronic Kidney Disease Requiring Chronic Dialysis, Vaccine Response | Recruiting | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 146 | 2024-10-16 | 2026-03-30 | |
| Covid-19 and Influenza Oral Vaccine Study Covid-19 vaccine, Influenza vaccine - covid19 Infection, Influenza, Human | Phase 1 | Recruiting | Vaxine Pty Ltd | 100 | 2024-05-01 | 2025-09-17 |
| Vaccine Responses in Cancer Influenza vaccination, SARS-CoV-2 vaccine, Zoster Vaccine Recombinant - Viral Vaccines | Active not recruiting | Abramson Cancer Center at Penn Medicine | 250 | 2022-11-04 | 2025-10-28 | |
| Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076) 9vHPV Vaccine, mRNA-1273 Vaccine - Papillomavirus Infections, Coronavirus Disease (COVID-19) | Phase 3 | Completed | Merck Sharp & Dohme LLC | 165 | 2022-03-28 | 2026-02-05 |
| COVID Protection After Transplant-Immunosuppression Reduction Pfizer-BioNTech COVID-19 Vaccine 2023-2024, Moderna COVID-19 Vaccine 2023-2024, SOC IS Regimen - Kidney Transplant Recipients, Liver Transplant Recipients | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 48 | 2021-12-06 | 2026-04-23 |
| Safety and Immune Response of COVID-19 Vaccination in Overweight People With Excessive BMI SARS-COV-2 VACCINE - Covid19, Overweight | Unknown | The Second Affiliated Hospital of Chongqing Medical University | 450 | 2021-08-01 | 2021-09-14 | |
| Safety and Immune Response of COVID-19 Vaccination in Patients With Basic Disease SARS-COV-2 VACCINE - Diseases, Chronic, Covid19 | Unknown | The Second Affiliated Hospital of Chongqing Medical University | 2300 | 2021-08-01 | 2022-08-10 | |
| Safety and Immune Response of COVID-19 Vaccination in Patients With Chronic Liver Diseases SARS-COV-2 VACCINE - Liver Diseases, Covid19 | Unknown | The Second Affiliated Hospital of Chongqing Medical University | 2000 | 2021-07-01 | 2021-08-16 | |
| Study of a Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Adjuvanted Inactivated Vaccine in Healthy Adults SARS-CoV-2 vaccine, Placebo - Covid19 | Phase 1 | Terminated | Osman ERGANIS, PhD, Prof | 50 | 2021-04-25 | 2023-04-18 |
| Humoral and Cellular Immunity Against SARS-COV-2 Vaccine in HIV-infected Patients Immunosuppressed SARS-CoV-2 Vaccine - SARS-CoV-2 RNA Vaccines, HIV Infection | Completed | Hospitales Universitarios Virgen del Rocío | 48 | 2021-04-01 | 2024-10-15 | |
| Antibody Detection of Vaccine-Induced Secretory Effects SARS-CoV-2 vaccine - Covid19, Humoral Acquired Immunodeficiency | Completed | Children's Hospital Medical Center, Cincinnati | 61 | 2021-02-19 | 2025-07-30 | |
| Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Immune Kidney Transplant Study (COVID-19) SARS-CoV-2 vaccine - Kidney Transplant Infection, SARS-CoV Infection | Completed | Oslo University Hospital | 200 | 2021-01-22 | 2026-10-19 | |
| COVID-19 Vaccines Associated Malaise SARS-CoV-2 vaccine - Vaccine Adverse Reaction | Completed | University Hospital, Caen | 1534706 | 2021-01-01 | 2022-05-05 |
COVID-19 (9) · Influenza, Human (4) · Severe Acute Respiratory Syndrome (2) · Chronic Disease (1) · Coronavirus Infections (1) · HIV Infections (1) · Liver Diseases (1) · Overweight (1) · Papillomavirus Infections (1) · Renal Insufficiency, Chronic (1)
The Second Affiliated Hospital of Chongqing Medical University (3) · Abramson Cancer Center at Penn Medicine (1) · Children's Hospital Medical Center, Cincinnati (1) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (1) · Hospitales Universitarios Virgen del Rocío (1) · Merck Sharp & Dohme LLC (1) · ModernaTX, Inc. (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Oslo University Hospital (1) · Osman ERGANIS, PhD, Prof (1) · University Hospital, Caen (1) · Vaxine Pty Ltd (1)
United States (4) · China (3) · Australia (1) · France (1) · Italy (1) · Japan (1) · Norway (1) · South Korea (1) · Spain (1) · Taiwan (1) · Turkey (Türkiye) (1)
Hong Ren, PH D (3) · Christian P. Larsen, MD, DPhil (1) · Dimitar Sajkov, MBBS/PhD (1) · Dorry L. Segev, MD, PhD (1) · E. John Wherry, PhD (1) · Julie Ware (1) · Oguz Akbas, MD (1) · Peter S. Heeger, MD (1) · Russell Ware (1)
PMID 32350462, PMID 32504052, PMID 32555424, PMID 33257893, PMID 35107848, PMID 36620297, PMID 36705404, PMID 36750902, PMID 36849838, PMID 36946505, PMID 37006309, PMID 37457966, PMID 37615566, PMID 42531981
U01AI138897 (1)